Department of Clinical Oncology, Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UK.
Hull and York Medical School, Heslington, UK.
Oncol Res Treat. 2023;46(7-8):312-319. doi: 10.1159/000531590. Epub 2023 Jun 16.
The concept of oligometastatic disease (OMD) was first introduced in 1995 by Hellman and Weichselbaum and described as stage of transition between localized and widespread metastatic disease. The presence of OMD in esophagogastric (OG) cancer remains controversial. Historically, most experts believe that OG cancer is systemic disease from the outset.
More recently, there is emerging data indicating improved outcomes in patients with OG cancer and oligometastatic disease. The present manuscript focuses on reviewing the emerging evidence in management of metastatic OG cancer with OMD and highlighting the direction of future research.
Multiple retrospective and at least 2 phase II retrospective studies have reported on improved outcomes in patients with metastatic OG cancer and OMD. There is indication of improved outcome with combined systemic and local therapy (surgery or radiation). Further research should include phase III randomized studies to identify the optimal management algorithm in these groups of patients.
寡转移疾病（OMD）的概念于 1995 年由 Hellman 和 Weichselbaum 首次提出，被描述为局限性和广泛性转移疾病之间的过渡阶段。在食管胃（OG）癌中存在 OMD 仍然存在争议。从历史上看，大多数专家认为 OG 癌症从一开始就是全身性疾病。
最近，有越来越多的数据表明，寡转移疾病的 OG 癌症患者的预后得到改善。本文重点回顾了 OG 癌症伴寡转移疾病的治疗中新兴的证据，并强调了未来研究的方向。
多项回顾性和至少 2 项 II 期回顾性研究报告称，寡转移 OG 癌症患者的预后得到改善。联合全身治疗和局部治疗（手术或放疗）的疗效更好。进一步的研究应包括 III 期随机研究，以确定这些患者群体的最佳治疗方案。
